Breakout Stocks
AMLX is part of our breakout stocks list, indicating it is showing strong recent technical strength.
AMYLYX PHARMACEUTICALS INC (AMLX) Stock Price & Overview
NASDAQ:AMLX • US03237H1014
Current stock price
17.73 USD
+0.61 (+3.56%)
At close:
17.9485 USD
+0.22 (+1.23%)
After Hours:
The current stock price of AMLX is 17.73 USD. Today AMLX is up by 3.56%. In the past month the price increased by 28.57%. In the past year, price increased by 345.48%.
AMLX Key Statistics
52-Week Range3.94 - 17.91
Current AMLX stock price positioned within its 52-week range.
1-Month Range12.68 - 17.91
Current AMLX stock price positioned within its 1-month range.
- Market Cap
- 1.96B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.55
- Dividend Yield
- N/A
AMLX Stock Performance
Today
+3.56%
1 Week
+2.37%
1 Month
+28.57%
3 Months
+23.99%
Longer-term
6 Months +18.60%
1 Year +345.48%
2 Years +879.56%
3 Years -37.57%
5 Years N/A
10 Years N/A
AMLX Stock Chart
AMLX Stock Screens
AMLX currently appears in the following ChartMill screener lists.
AMLX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to AMLX. When comparing the yearly performance of all stocks, AMLX is one of the better performing stocks in the market, outperforming 98.2% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
AMLX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AMLX. While AMLX has a great health rating, there are worries on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
AMLX Earnings
Next Earnings DateMay 7, 2026
Last Earnings DateMar 3, 2026
PeriodQ4 / 2025
EPS Reported-$0.30
Revenue Reported
EPS Surprise 18.03%
Revenue Surprise %
AMLX Forecast & Estimates
18 analysts have analysed AMLX and the average price target is 22.75 USD. This implies a price increase of 28.29% is expected in the next year compared to the current price of 17.73.
Analysts
Analysts86.67
Price Target22.75 (28.31%)
EPS Next Y9.26%
Revenue Next YearN/A
AMLX Groups
Sector & Classification
AMLX Financial Highlights
Over the last trailing twelve months AMLX reported a non-GAAP Earnings per Share(EPS) of -1.55. The EPS increased by 37.25% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-144.74M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -43.51% | ||
| ROE | -47.41% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%45.45%
Sales Q2Q%100%
EPS 1Y (TTM)37.25%
Revenue 1Y (TTM)-100%
AMLX Ownership
Ownership
Inst Owners96.92%
Shares110.54M
Float92.98M
Ins Owners8.07%
Short Float %15.31%
Short Ratio13.66
AMLX Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 25.85 | 855.09B | ||
| JNJ | JOHNSON & JOHNSON | 18.49 | 574.863B | ||
| MRK | MERCK & CO. INC. | 22.68 | 291.495B | ||
| PFE | PFIZER INC | 9.11 | 154.667B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.31 | 118.196B | ||
| ZTS | ZOETIS INC | 16.83 | 50.976B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.38 | 28.093B | ||
| VTRS | VIATRIS INC | 5.62 | 16.139B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.98 | 11.549B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.421B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.331B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.083B | ||
| CORT | CORCEPT THERAPEUTICS INC | 81.01 | 4.67B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find more ETFs on the USA exchanges | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About AMLX
Company Profile
Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). The company is headquartered in Cambridge, Massachusetts and currently employs 136 full-time employees. The company went IPO on 2022-01-07. The firm is focused on three investigational therapies across several neurodegenerative and endocrine diseases. Its lead investigational asset is avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. Avexitide has been evaluated as a treatment for Post-Bariatric Hypoglycemia (PBH) and congenital HI, two indications characterized by hyperinsulinemic hypoglycemia. In addition to avexitide, it is advancing AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in Wolfram syndrome and progressive supranuclear palsy (PSP), and AMX0114 in amyotrophic lateral sclerosis (ALS). AMX0035 is designed to mitigate neurodegeneration by targeting endoplasmic reticulum stress and mitochondrial dysfunction, two cellular processes central to neuronal cell death and neurodegeneration. AMX0114 is an investigational antisense oligonucleotide.
Company Info
IPO: 2022-01-07
AMYLYX PHARMACEUTICALS INC
55 Cambridge Parkway, Suite 6W
Cambridge MASSACHUSETTS US
Employees: 136
Phone: 16176820917
AMYLYX PHARMACEUTICALS INC / AMLX FAQ
What does AMLX do?
Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). The company is headquartered in Cambridge, Massachusetts and currently employs 136 full-time employees. The company went IPO on 2022-01-07. The firm is focused on three investigational therapies across several neurodegenerative and endocrine diseases. Its lead investigational asset is avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. Avexitide has been evaluated as a treatment for Post-Bariatric Hypoglycemia (PBH) and congenital HI, two indications characterized by hyperinsulinemic hypoglycemia. In addition to avexitide, it is advancing AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in Wolfram syndrome and progressive supranuclear palsy (PSP), and AMX0114 in amyotrophic lateral sclerosis (ALS). AMX0035 is designed to mitigate neurodegeneration by targeting endoplasmic reticulum stress and mitochondrial dysfunction, two cellular processes central to neuronal cell death and neurodegeneration. AMX0114 is an investigational antisense oligonucleotide.
What is the stock price of AMYLYX PHARMACEUTICALS INC today?
The current stock price of AMLX is 17.73 USD. The price increased by 3.56% in the last trading session.
Does AMLX stock pay dividends?
AMLX does not pay a dividend.
What is the ChartMill rating of AMYLYX PHARMACEUTICALS INC stock?
AMLX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the PE ratio for AMLX stock?
AMYLYX PHARMACEUTICALS INC (AMLX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.55).
What is the ownership structure of AMYLYX PHARMACEUTICALS INC (AMLX)?
You can find the ownership structure of AMYLYX PHARMACEUTICALS INC (AMLX) on the Ownership tab.